Premature Fatigue in Veterans With Heart Failure: Neuronal Influences

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-01

Study Completion Date

2017-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A hallmark of patients with heart failure (HF) is premature fatigue which impairs their quality of life and depicts a major source of morbidity. Premature fatigue may be attributed to a) contraction-induced transient changes within muscles (i.e. peripheral fatigue) and/or b) failure of the central nervous system to 'drive' / activate locomotor muscles (i.e. central fatigue). Both determinants of fatigue can lead to a reduction in a muscle's force and power generating capacity and to a compromised ability to perform whole body activities (e.g. walking). Recent findings in health have documented that group III/IV afferent fibers from the working muscle play a critical role in the development of both components of fatigue. Specifically, group III/IV muscle afferents limit central motor drive (CMD) during exercise and thereby exaggerate the development of central fatigue. In contrast, muscle afferents optimize muscle O2 delivery through the precise regulation of circulation and ventilation during exercise and thereby attenuate the development of peripheral fatigue.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Muscle Afferent Feedback Effects in Patients With Heart Failure

NCT01919918

Chronic Heart Failure

COMPLETED PHASE1

Cardiac Rehab Effects in HFpEF

NCT04506606

Heart Failure With Preserved Ejection Fraction

RECRUITING NA

Muscle Blood Flow Regulation in HFpEF

NCT05115890

HFpEF

RECRUITING NA

Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)

NCT03615469

Heart Failure

TERMINATED NA

The Utility of Focused Frailty Interventions on Patients With Advanced Heart Failure

NCT03574662

Heart Failure

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recent findings in HF suggest an altered effect of group III/IV muscle afferents in this population. Although normal afferent feedback is crucial for adequate O2 delivery during exercise, excessive neural feedback has substantial negative consequences. HF patients are characterized by augmented neural feedback arising from overactive muscle afferents. It has been hypothesized that this abnormality compromises locomotor muscle O2 delivery in these patients. Therefore, the abnormally elevated muscle afferent feedback in HF might exacerbate, compared to healthy age- and activity matched individuals (CTRLs), the development of both peripheral (via limiting O2 delivery) and central (via restricting CMD) fatigue during exercise. Recent advances in non-invasive stimulation techniques offer a genuine opportunity to identify the sites and synaptic mechanisms that mediate central and peripheral fatigue including alterations in the responsiveness of the corticospinal tract (i.e. a determinant of central fatigue). Taken together, the proposed studies aim to determine the impact of HF on the precise development of central and peripheral fatigue during both whole body and single muscle exercise and evaluate the extent to which group III/IV muscle afferents contribute to this development.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients With Heart Failure: Neuromuscular Abnormalities

Patients with Heart Failure

Group Type OTHER

Electrical and Magnetic Nerve Stimulators

Intervention Type DEVICE

Stimulation of motor nerve and central nervous system

Intrathecal Fentanyl

Intervention Type DRUG

Mu-opioid receptor agonist

Health Control Subjects and Neuromuscular Function

Health Control Subjects

Group Type OTHER

Electrical and Magnetic Nerve Stimulators

Intervention Type DEVICE

Stimulation of motor nerve and central nervous system

Intrathecal Fentanyl

Intervention Type DRUG

Mu-opioid receptor agonist

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electrical and Magnetic Nerve Stimulators

Stimulation of motor nerve and central nervous system

Intervention Type DEVICE

Intrathecal Fentanyl

Mu-opioid receptor agonist

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* subjects with a history of stable cardiomyopathy (ischemic and non-ischemic, \>1yr duration, ages 20-75 yr),
* not pacemaker dependent (no biventricular pacers),
* NYHA class II and III symptoms,
* Left ventricular ejection fraction (LVEF)\<35%,
* no or minimal smoking history (\<15 pk yrs) and on stable medications.
* The investigators will also study subjects with preserved ejection fraction

* heart failure with a preserved ejection fraction (HFpEF);
* LVEF \>50%,
* \>1yr duration,
* ages 20-75 yr,
* not pacemaker dependent,
* NYHA class II and III symptoms,
* no or minimal smoking history (\<15 pk yrs) and on stable medications. The investigators will exclude morbidly obese patients (BMI \>35), patients with uncontrolled hypertension (\>160/100), anemia (Hgb\<9) and severe renal insufficiency (individuals with creatinine clearance \<30 by the Cockcroft-Gault formula).

Exclusion Criteria

* Patients with significant non-cardiac comorbidities, which if present could alter the study results, will be excluded.
* Patients will be sedentary, defined here as no regular physical activity for at least the prior 6 months and current activity level will be documented by an activity questionnaire.
* Candidates must have no orthopedic limitations that would prohibit them from performing exercise.
* Due to the typical age of patients with heart failure, all women will be postmenopausal (either natural or surgical) defined as a cessation of menses for at least 2 years,

* and in women without a uterus, follicle stimulating hormone (FSH) \>40 IU/L.
* Women currently taking hormone replacement therapy (HRT) will be excluded from the proposed studies due to the direct vascular effects of HRT.
* Patients with a pacemaker and / or defibrillator will be excluded from the study due to the use of a magnetic/electric stimulators.

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes